A structurally similar ligand was shown to label α-synuclein pathology in both human PD cortical tissue sections and A30P transgenic mice brain sections.23 These promising binding properties, combined with the ease of synthesis and derivatisation of this class of molecules, led us to select BF-79 to use in this study. This evidence concerns the gene SNCA and Parkinson disease.